Enhanced TLR4 endothelial cell immunohistochemical expression in symptomatic carotid atherosclerotic plaques. 2010

Athanasios Katsargyris, and Stamatios E Theocharis, and Sotirios Tsiodras, and Konstantinos Giaginis, and Elias Bastounis, and Chris Klonaris
National and Kapodistrian University of Athens, School of Medicine, LAIKON Hospital, Vascular Division, 1st Department of Surgery, Goudi, GR11527, Athens, Greece.

OBJECTIVE Toll-like receptor-4 (TLR4) has been linked to the pathogenesis of atherosclerosis. Carotid atheroma endothelial cells (ECs) express TLR4, nevertheless correlations with cerebrovascular symptomatology, epidemiological and clinical variables remain unresolved. METHODS Carotid atherosclerotic plaques were obtained by standard carotid endarterectomy from 157 patients with carotid artery disease (84 asymptomatic - Group A, 73 symptomatic - Group B). TLR4 expression was detected by immunohistochemistry and TLR4 positivity, overexpression and intensity of immunostaining in ECs were correlated with cerebrovascular symptomatology, epidemiological and clinical variables. RESULTS A significant association was found between TLR4 positivity in ECs and the occurrence of any cerebrovascular event (overall response (OR): 2.85, 95% CI 1.33 - 6.11, p = 0.009). TLR4 overexpression and staining intensity in ECs were both significantly enhanced in symptomatic patients (p < 0.0001 and p = 0.003, respectively). These associations were stronger for the occurrence of a major cerebrovascular accident (CVA) compared with a transient ischemic attack (TIA) or amaurosis fugax. TLR4 expression in ECs was less prominent in statin users (OR: 0.25, 95%CI 0.1 - 0.58, p = 0.001], while it was enhanced in restenotic plaques compared with primary atherosclerotic lesions (p = 0.012). CONCLUSIONS TLR4 expression in ECs of carotid atheroma was enhanced in symptomatic patients with most commonly 'unstable' - 'more prone to rupture' carotid plaques.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008297 Male Males
D002097 C-Reactive Protein A plasma protein that circulates in increased amounts during inflammation and after tissue damage. C-Reactive Protein measured by more sensitive methods often for coronary heart disease risk assessment is referred to as High Sensitivity C-Reactive Protein (hs-CRP). High Sensitivity C-Reactive Protein,hs-CRP,hsCRP,C Reactive Protein,High Sensitivity C Reactive Protein
D002339 Carotid Arteries Either of the two principal arteries on both sides of the neck that supply blood to the head and neck; each divides into two branches, the internal carotid artery and the external carotid artery. Arteries, Carotid,Artery, Carotid,Carotid Artery
D002546 Ischemic Attack, Transient Brief reversible episodes of focal, nonconvulsive ischemic dysfunction of the brain having a duration of less than 24 hours, and usually less than one hour, caused by transient thrombotic or embolic blood vessel occlusion or stenosis. Events may be classified by arterial distribution, temporal pattern, or etiology (e.g., embolic vs. thrombotic). (From Adams et al., Principles of Neurology, 6th ed, pp814-6) Brain Stem Ischemia, Transient,Cerebral Ischemia, Transient,Crescendo Transient Ischemic Attacks,Transient Ischemic Attack,Anterior Circulation Transient Ischemic Attack,Brain Stem Transient Ischemic Attack,Brain TIA,Brainstem Ischemia, Transient,Brainstem Transient Ischemic Attack,Carotid Circulation Transient Ischemic Attack,Posterior Circulation Transient Ischemic Attack,TIA (Transient Ischemic Attack),Transient Ischemic Attack, Anterior Circulation,Transient Ischemic Attack, Brain Stem,Transient Ischemic Attack, Brainstem,Transient Ischemic Attack, Carotid Circulation,Transient Ischemic Attack, Posterior Circulation,Transient Ischemic Attack, Vertebrobasilar Circulation,Transient Ischemic Attacks, Crescendo,Vertebrobasilar Circulation Transient Ischemic Attack,Attack, Transient Ischemic,Attacks, Transient Ischemic,Brainstem Ischemias, Transient,Cerebral Ischemias, Transient,Ischemia, Transient Brainstem,Ischemia, Transient Cerebral,Ischemias, Transient Brainstem,Ischemias, Transient Cerebral,Ischemic Attacks, Transient,TIA, Brain,TIAs (Transient Ischemic Attack),Transient Brainstem Ischemia,Transient Cerebral Ischemia,Transient Cerebral Ischemias,Transient Ischemic Attacks
D005260 Female Females
D006083 Graft Occlusion, Vascular Obstruction of flow in biological or prosthetic vascular grafts. Graft Restenosis, Vascular,Vascular Graft Occlusion,Vascular Graft Restenosis,Graft Restenoses, Vascular,Occlusion, Vascular Graft,Restenosis, Vascular Graft
D006710 Homocysteine A thiol-containing amino acid formed by a demethylation of METHIONINE. 2-amino-4-mercaptobutyric acid,Homocysteine, L-Isomer,2 amino 4 mercaptobutyric acid,Homocysteine, L Isomer,L-Isomer Homocysteine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

Athanasios Katsargyris, and Stamatios E Theocharis, and Sotirios Tsiodras, and Konstantinos Giaginis, and Elias Bastounis, and Chris Klonaris
May 2008, Stroke,
Athanasios Katsargyris, and Stamatios E Theocharis, and Sotirios Tsiodras, and Konstantinos Giaginis, and Elias Bastounis, and Chris Klonaris
February 2019, Molecular biology reports,
Athanasios Katsargyris, and Stamatios E Theocharis, and Sotirios Tsiodras, and Konstantinos Giaginis, and Elias Bastounis, and Chris Klonaris
December 2004, Stroke,
Athanasios Katsargyris, and Stamatios E Theocharis, and Sotirios Tsiodras, and Konstantinos Giaginis, and Elias Bastounis, and Chris Klonaris
March 2012, Journal of neurology,
Athanasios Katsargyris, and Stamatios E Theocharis, and Sotirios Tsiodras, and Konstantinos Giaginis, and Elias Bastounis, and Chris Klonaris
July 2015, IEEE journal of biomedical and health informatics,
Athanasios Katsargyris, and Stamatios E Theocharis, and Sotirios Tsiodras, and Konstantinos Giaginis, and Elias Bastounis, and Chris Klonaris
July 2023, Vascular,
Athanasios Katsargyris, and Stamatios E Theocharis, and Sotirios Tsiodras, and Konstantinos Giaginis, and Elias Bastounis, and Chris Klonaris
January 2005, International journal of immunopathology and pharmacology,
Athanasios Katsargyris, and Stamatios E Theocharis, and Sotirios Tsiodras, and Konstantinos Giaginis, and Elias Bastounis, and Chris Klonaris
January 2008, Journal of clinical ultrasound : JCU,
Athanasios Katsargyris, and Stamatios E Theocharis, and Sotirios Tsiodras, and Konstantinos Giaginis, and Elias Bastounis, and Chris Klonaris
August 2007, Experimental and molecular pathology,
Athanasios Katsargyris, and Stamatios E Theocharis, and Sotirios Tsiodras, and Konstantinos Giaginis, and Elias Bastounis, and Chris Klonaris
May 2010, Nuclear medicine communications,
Copied contents to your clipboard!